{
  "eval_id": "S48",
  "timestamp": "2025-09-19T09:05:45.288630+00:00",
  "model": "gpt-4o",
  "temperature": 0.6,
  "rep_input": "Patient HR+/HER2- progressed after CDK4/6; what key label-based caveats should I discuss?",
  "model_output": "In this scenario, consider the patientâ€™s performance status and any visceral disease. For HR+/HER2- after CDK4/6 progression, options may include endocrine therapies or chemotherapy, guided by the label. Please refer to the SmPC or EPAR for specific data and details."
}